Biocon inks patent litigation settlement pact with Celgene

PTI New Delhi | Updated on September 08, 2021

Biocon shares were trading 0.45% up on BSE

Biotechnology major Biocon on Wednesday said it has entered into a settlement with Celgene Corporation regarding patents for Revlimid, a medication used to treat bone marrow cancer.

The company along with its subsidiaries has entered into a confidential settlement agreement with Celgene Corporation, a wholly-owned subsidiary of Bristol Myers Squibb, relating to patents for Revlimid (lenalidomide), the Bengaluru-based company said in a regulatory filing.

It did not share details of the agreement.

Celgene had filed a complaint in the US, against Biocon for potential patent infringement.

Biocon shares were trading 0.45 per cent up at ₹358.30 apiece on BSE.

Published on September 08, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like